The present invention pertains to: an oxidation color developable compound that is represented by general formula (1), that has excellent solubility in water, and that is less affected by a substance coexisting in a sample; and an oxidation color development reagent using the oxidation color developable compound. In general formula (I), R.sup.1, R.sup.2, R.sup.3, and R.sup.4 each represent a straight-chain or branched alkyl group having 1-6 carbon atoms, X represents a hydrophilic functional group, and L represents (CH.sub.2).sub.j (j represents an integer of 2-10), (CH.sub.2CH.sub.2O).sub.k (k represents an integer of 1-10), or (CH.sub.2).sub.mZ(CH.sub.2).sub.n (m and n each independently represent an integer of 1-10, and Z represents N.sup.+(CH.sub.3).sub.2, CONH, NHCO, COO, OCO, NHCOO, OCONH, NHCONH, and (CH.sub.2NHCO).sub.q).

Systems and methods are provided for diagnosing cancer by using promoter methylation as an indicator of interest. Key promoter regions of interest are first identified via supervised or unsupervised machine learning applied to the Cancer Genome Atlas via a silico predictive tool. After this, a specially-designed assay is used to detect the presence of these hyper-methylated regions of interest and provide a quantitative, fluorescent readout in order to generate clinical insight. In addition, special advances in material science and microfluidics are used to enhance the sensitivity and specificity of the assay. The workflow is then completed via integration into a smartphone application that provides the necessary data and helps streamline doctor-patient communication.

Systems and methods are provided for diagnosing cancer by using promoter methylation as an indicator of interest. Key promoter regions of interest are first identified via supervised or unsupervised machine learning applied to the Cancer Genome Atlas via a silico predictive tool. After this, a specially-designed assay is used to detect the presence of these hyper-methylated regions of interest and provide a quantitative, fluorescent readout in order to generate clinical insight. In addition, special advances in material science and microfluidics are used to enhance the sensitivity and specificity of the assay. The workflow is then completed via integration into a smartphone application that provides the necessary data and helps streamline doctor-patient communication.

The claimed invention provides real-time and subsequent analysis personalized user based health, wellness and pharmaceutical and illicit drug detection information. Non-invasive techniques utilize saliva for body levels of wellness indicators and pharmaceutical and illicit drug ingestion which are coordinated over time. Saliva captured on sample strips are real-time indicator reviewed and subsequently analyzed using traditional analytical chemistry techniques including liquid chromatography/mass spectrometry (LC/MS) and coordinated with time of administration with optional genetic sequence analysis to confirm related disease conditions. By using P4 (Participatory, Personalized, Predictive, and Preventive) health management techniques the patient determines if the pharmaceutical is having the correct and desired effect for maximum therapeutic benefit. While illustrative embodiments detecting Metformin and Keppra are provided the system has broad pharmaceutical and illicit drug monitoring applicability.

The claimed invention provides real-time and subsequent analysis personalized user based health, wellness and pharmaceutical and illicit drug detection information. Non-invasive techniques utilize saliva for body levels of wellness indicators and pharmaceutical and illicit drug ingestion which are coordinated over time. Saliva captured on sample strips are real-time indicator reviewed and subsequently analyzed using traditional analytical chemistry techniques including liquid chromatography/mass spectrometry (LC/MS) and coordinated with time of administration with optional genetic sequence analysis to confirm related disease conditions. By using P4 (Participatory, Personalized, Predictive, and Preventive) health management techniques the patient determines if the pharmaceutical is having the correct and desired effect for maximum therapeutic benefit. While illustrative embodiments detecting Metformin and Keppra are provided the system has broad pharmaceutical and illicit drug monitoring applicability.

A sensor determines whether a specimen includes a first substance. In an exemplary embodiment, the sensor includes a base. In an exemplary embodiment, the sensor is configured to determine whether the specimen includes the first substance and further includes, on the base, a detection unit on which a second substance is immobilized. The second substance includes a bond that is cleft by the reaction with hydrogen peroxide. In an exemplary embodiment, the specimen that is brought in contact with an enzyme that generates the hydrogen peroxide by the reaction with the first substance is introduced to the detection unit in the sensor configured to determine whether the specimen includes the first substance.

A sensor determines whether a specimen includes a first substance. In an exemplary embodiment, the sensor includes a base. In an exemplary embodiment, the sensor is configured to determine whether the specimen includes the first substance and further includes, on the base, a detection unit on which a second substance is immobilized. The second substance includes a bond that is cleft by the reaction with hydrogen peroxide. In an exemplary embodiment, the specimen that is brought in contact with an enzyme that generates the hydrogen peroxide by the reaction with the first substance is introduced to the detection unit in the sensor configured to determine whether the specimen includes the first substance.

The disclosure provides compositions, kits and methods comprising an absorbent pad comprising a fibrous material and a liquid formulation comprising a luminescent substrate for identifying and quantifying biomolecule analytes.

The disclosure provides compositions, kits and methods comprising an absorbent pad comprising a fibrous material and a liquid formulation comprising a luminescent substrate for identifying and quantifying biomolecule analytes.

The subject invention provides methods, assays, and products for visual detection of small-molecule targets in a sample in both clinical and field settings within minutes. The subject invention is based on an aptamer sensor that reports the presence of small-molecule target via a sensitive colorimetric signal for naked-eye detection. The aptamer sensor is a CBSAzyme-based sensor having both target-mediated cooperative behavior of the CBSA and peroxidase-mimicking catalytic activity of DNAzyme. The subject invention also provides methods of using the CBSAzyme-based sensor.